Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
Date:10/29/2008

SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its third quarter financial results after the market closes on Thursday, November 6, 2008.

Cadence management will host a conference call and live webcast to discuss the financial results and provide a clinical program update on Thursday, November 6, 2008 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Interested investors may participate in the conference call by dialing 866-816-1982 (domestic) or 816-581-1712 (international). To access the webcast, please visit the company's website at http://www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue

SVP & Chief Financial Officer

Cadence Pharmaceuticals, Inc.

858-436-1400

Anna Gralinska

Director, Investor Relations

Cadence Pharmaceuticals, Inc.

858-436-1452


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
6. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008
7. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
8. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
9. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
10. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... DUBLIN , March 27, 2017 ... access to a comprehensive library of reports on Valero ... the transportation fuels and petrochemical industries. ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) ... is biofuel production to go green. Ethanol today, even though ...
(Date:3/27/2017)... , March 27, 2017  Trovagene, Inc. (NASDAQ: TROV), ... Chief Executive Officer, Bill Welch , will be ... 2017 at 9:00 AM EDT at the Essex House ... Welch, and Chief Scientific Officer, Mark Erlander , ... during the conference.   The presentation will be ...
(Date:3/24/2017)... , March 24, 2017 MiMedx Group, Inc. ... utilizing human placental tissue allografts and patent-protected processes to ... sectors of healthcare, announced today  that it will present ... York , NY.  Parker H. "Pete" Petit, Chairman ... Officer, Christopher M. Cashman , EVP and Chief ...
(Date:3/24/2017)... Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of ... its board of directors has amended its shareholder rights plan. The amendment ... to March 27, 2018. The amendment was not in response to any ... ... is a China -based biopharmaceutical company that focuses ...
Breaking Biology Technology:
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited ... to the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... the largest German biometrics company the two government leaders could see the ... well as DERMALOG´s multi-biometrics system.   Continue Reading ... ...
(Date:3/13/2017)... HAMBURG, Germany , March 13, 2017 Future of ... ... DERMALOGs Face Matching enables to match ... characteristics forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for ...
(Date:3/7/2017)... -- Brandwatch , the leading social intelligence company, today announces ... to uncover insights to support its reporting, help direct future campaigns, ... leading youth charity will be using Brandwatch Analytics social listening and ... understanding of the topics and issues that are a priority for ... "Until ...
Breaking Biology News(10 mins):